RxDoctor Payments Data

Mary Newton-Butler

Family · Laurinburg, NCNPI 1356683106

Payments from drug & device makers

$1,521in general payments, 2019–2025

Across 94 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$341
  • AbbVie$322
  • Lilly USA, LLC$187
  • Amgen$131
  • AstraZeneca$110
  • Pfizer$67
  • plus $363 from 15 others

What the payments were for

  • Food & beverage$1,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,521 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,227
Medicare patients
120
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide121$156,614
OzempicSemaglutide120$155,568
JardianceEmpagliflozin76$83,944
EliquisApixaban46$53,892
LinzessLinaclotide67$46,418
TrulicityDulaglutide19$45,040
TradjentaLinagliptin24$26,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,620
FarxigaDapagliflozin Propanediol34$25,367
JanuviaSitagliptin Phosphate20$17,786
XareltoRivaroxaban26$17,704
UbrelvyUbrogepant12$11,270
VascepaIcosapent Ethyl24$8,433
Spiriva HandihalerTiotropium Bromide13$7,548
Janumet XrSitagliptin Phos/Metformin Hcl11$5,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$187$201,654140 claims
Novo NordiskOzempic$341$155,568120 claims
Boehringer IngelheimJardiance, Tradjenta$15$110,934100 claims
AbbVieLinzess, Ubrelvy$322$57,68879 claims
PfizerEliquis$67$53,89246 claims
AstraZenecaFarxiga$110$25,36734 claims
Johnson & JohnsonXarelto$26$17,70426 claims
Sanofi-aventis U.S. LLCLantus$55$3,12011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Laurinburg

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →